Table 3.
Drug response SNPs
| # | Drug/Condition | Chromosomal location | Gene | Genotype | SNP-ID | Drug related outcome |
|---|---|---|---|---|---|---|
| 1 |
Interferon beta therapy for multiple sclerosis (MS) |
chr13:92884370 |
GPC5 |
CT |
rs7987675 |
will likely not show increase response to interferon beta therapy in case of relapsed MS |
| 2 |
Lumiracoxib-related liver toxicity |
chr6:32305978 |
C6orf10 |
GT |
rs3129900 |
increase in liver toxicity risk in response to lumiracoxib used to treat acute pain and osteoarthritic symptoms |
| 3 |
Metformin Response |
chr11:108239628 |
ATM-C11orf65 |
GG |
rs4585 |
will respond better to Metformin |
| 4 |
Ribavirin-induced anemia |
chr20:3193842 |
ITPA |
CA |
rs1127354 |
greatly decreased odds of developing anemia when taking PEG-IFN/RBV |
| 5 |
Statin induced myopathy |
chr12:21331549 |
SLCO1B1 |
TT |
rs4149056 |
typical dose of Simvastin will not increase myopathy risk |
| 6 |
Floxacillin and liver toxicity |
chr6:31431780 |
HCP5 |
TT |
rs2395029 |
at typical dose liver toxicity is not expected in response to floxacillin |
| 7 |
Beta-Blocker - heart failure risk |
chr10:115805056 |
ADRB1 |
CC |
rs1801253 |
Bucindolol is unlikely to reduce mortality odds in case of heart failure |
| 8 |
Response to amitriptyline |
chr7:87160561 |
ABCB1 |
AA |
rs2032583 |
typical response to depression when treated with Elavil, Paxil, Effexor, or Celexa |
| 9 |
Warfarin sensitivity |
chr10:96702047 |
CYP2C9 |
CC |
rs1799853 |
typical dose of warfarin does not increase risk of bleeding |
| chr10:96741053 |
CYP2C9 |
AA |
rs1057910 |
|||
| chr16:31107689 |
VKORC1 |
CC |
rs9923231 |
|||
| promoter | ||||||
| 10 | Fluorouracil toxicity | chr1:97915613 | DPYD | CC | rs3918290 | No copies of the DPYD*2A mutation. May still be at risk for 5-FU toxicity due to other genetic or non-genetic factors |